8-KLeadership ChangesShareholder MattersExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jun 16, 2020)

Filed June 16, 2020For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 16, 2020, detailing the outcomes of its 2020 Annual Meeting of Shareholders held on June 12, 2020. The key information for investors revolves around the shareholder approval of the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan. This plan, previously adopted by the Board of Directors, received shareholder approval, which is a crucial step in the company's executive and employee compensation strategy. The filing also confirms the election of Class II directors and one Class III director, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and an advisory vote approving the compensation of the company's named executive officers. These items reflect routine corporate governance matters, with the incentive plan approval being the most significant operational update from this filing.

Key Highlights

  • 1Shareholders approved the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan.
  • 2Several Class II directors and one Class III director were elected to the Board.
  • 3PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
  • 4An advisory vote on executive compensation for named executive officers was approved by shareholders.
  • 5The company filed an 8-K on June 16, 2020, reporting on the June 12, 2020 Annual Meeting of Shareholders.
  • 6The approved Long-Term Incentive Plan is a key element of the company's compensation structure, designed to align executive and employee interests with long-term company performance.

Frequently Asked Questions

This 8-K filing was made to report the results of Regeneron's 2020 Annual Meeting of Shareholders, which included votes on director elections, auditor ratification, an updated long-term incentive plan, and executive compensation.

Yes, the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan was approved by shareholders at the Annual Meeting.

PricewaterhouseCoopers LLP was ratified by shareholders to serve as Regeneron's independent registered public accounting firm for the fiscal year ending December 31, 2020.

Shareholders approved, on an advisory basis, the compensation of the company's named executive officers as disclosed in the Proxy Statement.